Protalix BioTherapeutics, Inc.
PLX
$1.93
$0.021.05%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -49.93% | -0.60% | 16.21% | 169.82% | 73.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -49.93% | -0.60% | 16.21% | 169.82% | 73.74% |
| Cost of Revenue | 44.51% | -0.61% | -37.92% | 214.37% | -35.38% |
| Gross Profit | -837.37% | -0.59% | 143.60% | 68.67% | 113.28% |
| SG&A Expenses | 17.57% | 12.87% | -24.68% | -16.44% | -27.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.17% | 12.54% | -8.90% | 65.71% | -31.63% |
| Operating Income | -164.61% | -46.60% | 148.29% | 14.64% | 228.39% |
| Income Before Tax | -165.28% | -41.74% | 129.09% | 21.15% | 213.85% |
| Income Tax Expenses | -11.44% | -119.11% | 820.29% | 18.12% | 315.18% |
| Earnings from Continuing Operations | -184.76% | -27.22% | 107.44% | 21.24% | 207.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -184.76% | -27.22% | 107.44% | 21.24% | 207.45% |
| EBIT | -164.61% | -46.60% | 148.29% | 14.64% | 228.39% |
| EBITDA | -156.62% | -42.06% | 172.68% | 16.21% | 242.27% |
| EPS Basic | -174.81% | -32.50% | 106.98% | 24.96% | 211.18% |
| Normalized Basic EPS | -157.60% | -45.87% | 127.32% | 24.94% | 217.72% |
| EPS Diluted | -208.81% | -1.00% | 106.64% | 24.96% | 176.44% |
| Normalized Diluted EPS | -185.62% | -41.55% | 126.29% | 24.94% | 179.20% |
| Average Basic Shares Outstanding | 13.23% | 7.79% | 7.31% | 4.90% | -3.30% |
| Average Diluted Shares Outstanding | -23.79% | -0.50% | 10.86% | 4.90% | 43.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |